A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs BT 063 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Proof of concept
- Sponsors Biotest AG
- 19 Apr 2018 This trial has been completed in Poland (end date: 2017-10-25)
- 11 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.